GMAB vs. NVS: Genmab vs. Novartis Stock Comparison

Company Profile

Genmab (GMAB) and Novartis (NVS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but GMAB is classified in Biotechnology while NVS is classified in Pharmaceuticals.

Both Genmab (GMAB) and Novartis (NVS) trade as ADRs — their core financials are comparable, but keep FX, depositary-program fees, and dividend withholding in view for each.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Genmab (GMAB) at 12.07% and Novartis (NVS) at 24.33% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

For every dollar of sales, both Genmab (GMAB) at 16.97% and Novartis (NVS) at 17.49% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

Both Genmab (GMAB) at 37.15% and Novartis (NVS) at 34.27% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Genmab (GMAB) at 19.19% and Novartis (NVS) at 9.57% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both Genmab (GMAB) at -9.23% and Novartis (NVS) at 21.81% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Growth Metrics

Financial Strength

Both Genmab (GMAB) at 2.45 and Novartis (NVS) at 0.88 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both Genmab (GMAB) at 0.82 and Novartis (NVS) at 1.29 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.

Financial Strength Metrics

Dividends

Genmab (GMAB) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novartis (NVS) reports a yield of 2.88%, ranking against industry peers normally.

Genmab (GMAB) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novartis (NVS) reports a payout of 90.46%, ranking against industry peers normally.

Dividend Metrics

Valuation

Novartis (NVS) at 31.02 is near its industry’s usual P/E ratio, while Genmab (GMAB) at 45.84 sits in the richer quartile — GMAB needs stronger growth or earnings quality to justify the premium.

On P/S ratio, both Genmab (GMAB) at 7.68 and Novartis (NVS) at 5.35 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Genmab (GMAB) at 5.36 is valued about in line with its industry on P/B ratio, while Novartis (NVS) at 8.25 carries an above-peer premium to book — NVS is pricier on assets.

Valuation Metrics